Pfizer Announces Revised Bonus Scheme and Restructures Anti-Infectives Team Amid Portfolio Optimization

On the 11th, Pfizer’s PBG AI team announced the latest bonus policy for Q2. In light of the pandemic’s impact on different regions, a guaranteed minimum bonus of RMB 4,000 has been added for Q2. Meanwhile, performance assessment criteria have been adjusted by product (with Zithromax assessed separately) and by month, including modifications to discount standards. Additionally, bundled thresholds, completion-rate requirements, and other restrictions associated with various awards have been eliminated.

▌ Product Line Optimization

In the new market environment, many pharmaceutical companies are optimizing their product portfolios. The day before yesterday, Pfizer PBG also announced structural adjustments to its Anti-Infectives team, transferring Tigecycline and Vfend from the AI3 product line to AI1 and AI2, respectively. Overall, this optimization enhances the specialization of four teams, focusing on further segmented areas of Gram-negative bacteria, Gram-positive bacteria, and fungal infections. Zithromax (Azithromycin), now separated, is expected to focus on the outpatient market in the future.

Azithromycin tablets and capsules are included in the second batch of China’s National Centralized Drug Procurement. The winning bidders include CSPC Ouyi Pharmaceutical, Beijing Sihuan Pharmaceutical, China Resources Sanjiu Zhongyi Pharmaceutical, and Suzhou Erye Pharmaceutical. Following the nationwide implementation of the second batch of national centralized procurement this month, Pfizer’s Zithromax is expected to experience a slight impact on its market share; however, fortunately, these procured products do not represent the primary dosage forms of Zithromax.